Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 versus FACTIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 versus FACTIVE.
CIPROFLOXACIN IN DEXTROSE 5% vs FACTIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg IV every 8 hours.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
None Documented
None Documented
Terminal elimination half-life 3.5-5 hours in healthy adults, prolonged to 6-10 hours in elderly or mild renal impairment, and up to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Renal excretion accounts for approximately 50-70% of an administered dose as unchanged drug; biliary/fecal excretion accounts for about 20-35% (including active drug and metabolites).
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic